Journal
RHEUMATOLOGY
Volume 48, Issue 10, Pages 1190-1196Publisher
OXFORD UNIV PRESS
DOI: 10.1093/rheumatology/kep199
Keywords
Advanced glycation end products; Receptor for advanced glycation end products; Soluble form of receptor for advanced glycation end products; Biomarker; Atherosclerosis; Inflammation; Chronic inflammatory diseases
Categories
Ask authors/readers for more resources
The formation of advanced glycation end products (AGEs) is a result of the non-enzymatic reaction between sugars and free amino groups of proteins. AGEs, through interacting with their specific receptor for AGES (RAGE), result in activation of pro-inflammatory states and are involved in numerous pathologic situations. The soluble form of RAGE (sRAGE) is able to act as a decoy to avoid interaction of RAGE with its pro-inflammatory ligands (AGEs, HMGB1, S100 proteins). sRAGE levels have been found to be decreased in chronic inflammatory diseases including atherosclerosis, diabetes, renal failure and the aging process. The use of measuring circulating sRAGEs may prove to be a valuable vascular biomarker and in this review, we describe the implications of sRAGE in inflammation and propose that this molecule may represent a future therapeutic target in chronic inflammatory diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available